BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16388501)

  • 1. Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.
    Bjartell A; Johansson R; Björk T; Gadaleanu V; Lundwall A; Lilja H; Kjeldsen L; Udby L
    Prostate; 2006 May; 66(6):591-603. PubMed ID: 16388501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
    Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
    Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.
    Hoogland AM; Dahlman A; Vissers KJ; Wolters T; Schröder FH; Roobol MJ; Bjartell AS; van Leenders GJ
    BJU Int; 2011 Oct; 108(8):1356-62. PubMed ID: 21410630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer.
    Kosari F; Asmann YW; Cheville JC; Vasmatzis G
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1419-26. PubMed ID: 12433721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples.
    Festuccia C; Angelucci A; Gravina GL; Muzi P; Miano R; Vicentini C; Bologna M
    Int J Oncol; 2005 May; 26(5):1353-62. PubMed ID: 15809728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
    Zhigang Z; Wenlv S
    Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low salivary dehydroepiandrosterone and androgen-regulated cysteine-rich secretory protein 3 levels in Sjögren's syndrome.
    Laine M; Porola P; Udby L; Kjeldsen L; Cowland JB; Borregaard N; Hietanen J; Ståhle M; Pihakari A; Konttinen YT
    Arthritis Rheum; 2007 Aug; 56(8):2575-84. PubMed ID: 17665393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
    Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
    Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
    Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
    Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
    Thomas LN; Douglas RC; Vessey JP; Gupta R; Fontaine D; Norman RW; Thompson IM; Troyer DA; Rittmaster RS; Lazier CB
    J Urol; 2003 Nov; 170(5):2019-25. PubMed ID: 14532845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.
    Mikolajczyk SD; Millar LS; Wang TJ; Rittenhouse HG; Marks LS; Song W; Wheeler TM; Slawin KM
    Cancer Res; 2000 Feb; 60(3):756-9. PubMed ID: 10676664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cathepsin B expression in prostate cancer of native Japanese and Japanese-American patients: an immunohistochemical study.
    Sinha AA; Morgan JL; Betre K; Wilson MJ; Le C; Marks LS
    Anticancer Res; 2008; 28(4B):2271-7. PubMed ID: 18751406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.
    Aslan G; Irer B; Tuna B; Yorukoglu K; Saatcioglu F; Celebi I
    Pathol Res Pract; 2006; 202(2):93-8. PubMed ID: 16413692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
    Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R
    Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
    Thomas LN; Lazier CB; Gupta R; Norman RW; Troyer DA; O'Brien SP; Rittmaster RS
    Prostate; 2005 May; 63(3):231-9. PubMed ID: 15538746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer.
    Kanoh Y; Akahoshi T; Ohara T; Ohtani N; Mashiko T; Ohtani S; Egawa S; Baba S
    Anticancer Res; 2002; 22(3):1813-7. PubMed ID: 12168874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer.
    Bjartell A; Paju A; Zhang WM; Gadaleanu V; Hansson J; Landberg G; Stenman UH
    Prostate; 2005 Jun; 64(1):29-39. PubMed ID: 15651064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.
    Zhang WM; Finne P; Leinonen J; Stenman UH
    Scand J Clin Lab Invest Suppl; 2000; 233():51-8. PubMed ID: 11317942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.